The limited data that currently exist for the role of Ca 2ϩ /calmodulin-dependent protein kinase II (CaMKII) in neuropathic pain are conflicting. In the present study, we tested the hypothesis that CaMKII is required for the maintenance of neuropathic pain in a rodent model of experimental mononeuropathy. Spinal nerve L 5 /L 6 ligation (SNL) was found to increase the spinal activity of CaMKII (pCaMKII) on the ipsilateral (but not contralateral) side. This effect was blocked by 2-[N-(2-hydroxyethyl)-N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-Nmethylbenzylamine) (KN93) (intrathecal injection), a CaMKII inhibitor. Acute treatment with KN93 dose-dependently reversed SNL-induced thermal hyperalgesia and mechanical allodynia. The action of KN93 lasted for at least 2 to 4 h. 2-[N-(4-Methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-Nmethylbenzylamine (KN92) (45 nmol i.t.), an inactive analog of KN93, showed no effect on SNL-induced CaMKII activation, allodynia, or hyperalgesia. We further examined the pharmacologic action of trifluoperazine, a clinically used antipsychotic drug that we found to be a potent CaMKII inhibitor in these assays. Trifluoperazine (administered intraperitoneally or by mouth) dose-dependently reversed SNL-induced mechanical allodynia, thermal hyperalgesia, and CaMKII activation without causing locomotor impairment in mice at the highest doses used. In conclusion, our findings support a critical role of CaMKII in neuropathic pain. Blocking CaMKII or CaMKII-mediated signaling may offer a novel therapeutic target for the treatment of neuropathic pain.
Peripheral nerve injury often leads to pathologic persistent pain that can be presented with spontaneous pain, hyperalgesia, and allodynia (Dubner and Ruda, 1992; McMahon et al., 1993; Willis, 2001) . Central sensitization, as a result of neuronal plasticity, is considered a pivotal mechanism leading to the development of hyperalgesia and allodynia (Woolf, 2007; Pezet et al., 2008) . Although the specific pathways have yet to be elucidated, the N-methyl-D-aspartate (NMDA) receptors have been implicated consistently in the development of central sensitization (Woolf and Thompson, 1991; Wang et al., 2005) . Not surprisingly, the blockade of the NMDA receptors has been shown to prevent or disrupt pain behaviors in experimental models of neuropathic pain (e.g., Seltzer et al., 1991; Dickenson et al., 1997) . Activation of the NMDA receptors leads to increased Ca 2ϩ influx into the cytosol. This increased Ca 2ϩ influx initiates cascades of intracellular signaling events involving Ca 2ϩ and various protein kinases (Womack et al., 1988) . Numerous studies have suggested that the Ca 2ϩ -mediated cell signaling pathways are crucial to nociception (e.g., Saegusa et al., 2001; Kim et al., 2003) . In particular, Ca 2ϩ activates protein kinase C, specific isoforms of which have been demonstrated to be important in studies employing various experimental neuropathic pain models (Malmberg et al., 1997; Hua et al., 1999; Dina et al., 2000) .
Limited studies have been reported for another major intracellular protein kinase that is involved in Ca 2ϩ signaling, namely, Ca 2ϩ /calmodulin-dependent protein kinase II (CaMKII). Accounting for approximately 1 to 2% of total brain protein mass, CaMKII is ubiquitously distributed in the central nervous system. CaMKII is a serine/threonine protein kinase and, like protein kinase C, is activated by Ca 2ϩ signaling (Lisman et al., 2002) . A significant increase in intracellular Ca 2ϩ , which is found in chronic pain states (e.g., Eisenach et al., 2005) , first activates calmodulin (CaM) by binding to its Ca 2ϩ -binding sites. This interaction leads to a change in the conformation of CaM. CaMKII is then acti-vated by Ca 2ϩ /CaM by switching to an active state on exposure to Ca 2ϩ /CaM. Although the pathway stated above has been well accepted, the actual role of CaMKII in neuropathic pain has yet to be established. The limited data in the literature are somewhat conflicting. One group found that, at very low doses, the CaMKII inhibitors, KN93 (120 pmol i.t.) and myristoyl-autocamtide 2-related inhibitory peptide (1 nmol i.t.), reversed chronic constriction injury (CCI)-induced neuropathic pain in mice (Garry et al., 2003) . Another study reported a mixed effect that KN93 was capable of preventing, but not reversing, thermal hyperalgesia and mechanical allodynia after CCI . A third study found that nerve injury produced a similar enhancement of thermal and mechanical sensitivity in wild-type mice and CaMKII␣(T286A) mutant mice lacking the functional CaMKII␣ (Zeitz et al., 2004) . Our previous study, using a complete Freund's adjuvant (CFA)-induced persistent inflammation pain model, suggested that some of the conflicting results may be reconciled by examining the degree of CaMKII activity in the pre-versus post-treatment states. Therefore, it is critical to ensure CaMKII inhibition as verified by biochemical methods in such studies involving a protein kinase inhibitor or activator (Luo et al., 2008) . In this study, we tested the hypothesis that sufficient CaMKII inhibition is capable of acutely reversing the established spinal nerve ligation-induced pain behaviors. This was accomplished by examining the behavioral/biochemical correlation after treatments with CaMKII inhibitors. Investigating an acute action of CaMKII inhibition in chronic pain is critical not only for our understanding of the mechanisms but more importantly for designing useful drug therapies for neuropathic pain.
Materials and Methods
Materials. KN92 and KN93 were purchased from Calbiochem (San Diego, CA). Trifluoperazine dihydrochloride and other chemicals were obtained from Sigma-Aldrich (St. Louis, MO). Male ICR mice (25 Ϯ 5 g, Harlan, Indianapolis, IN) were provided food and water ad libitum with a 10:14-h light/dark cycle. Mice were randomly assigned to experimental groups according to a computer-generated randomization list. All animal experiments were carried out in accordance with the International Association for the Study of Pain and the National Institute of Health Guidelines for the handling and use of laboratory animals after approval by the University of Illinois Institutional Animal Care and Use Committee.
Drug Administration. Intrathecal injection was performed as described previously (Hylden and Wilcox, 1980; Luo et al., 2008) . A drug in a volume of 5 l was given by percutaneous puncture through an intervertebral space at the level of the fifth or sixth lumbar vertebra. A lateral tail-flick was used to verify the success of injection. For acute reversal experiments, mice were given KN93 (15-45 nmol i.t.), KN92 (45 nmol i.t.), or trifluoperazine (0.1-0.5 mg/kg i.p. or 0.1-1.0 mg/kg via gastric gavage) before pain testing on day 5 after nerve ligation. In these studies, control mice received an equal volume of saline.
Spinal Nerve Ligation. Spinal nerve ligation (SNL) operation was performed as published previously (Kim and Chung, 1992; Wang et al., 2001) . Separate groups of eight mice had the left L 5 and L 6 spinal nerves tightly ligated distal to the dorsal root ganglion but before the fibers join to form the sciatic nerve; the sham operation consisted of the same surgery but without nerve ligations. Mice were tested for thermal hyperalgesia and tactile allodynia (see below) before and at different time points after the SNL operation.
Mechanical Allodynia. Mechanical sensitivity was determined by the use of calibrated von Frey filaments (Stoelting, Wood Dale, IL) as described previously (Chaplan et al., 1994; Tang et al., 2007; Luo et al., 2008) . These tests were performed before surgery to obtain the baseline sensitivity and daily after SNL by the same researcher. On the day of drug intervention, response to mechanical sensitivity was determined at 0, 0.5, 2, 4, 8, and 24 h after the administration of a drug or vehicle. The up-down paradigm was used to determine 50% probability of paw withdrawal threshold (Dixon, 1980; Chaplan et al., 1994; Luo et al., 2008) .
Thermal Hyperalgesia. The paw withdrawal latencies to radiant heat were tested by the use of a plantar tester (model 7372; Ugo Basile, Comerio, Italy) as described previously (Hargreaves et al., 1988; Tang et al., 2007; Luo et al., 2008) . Mice were placed in a transparent cage on a glass floor. The radiant heat source was focused on the central portion of the plantar surface of the left hind paw, and paw withdrawal latencies were recorded when the heat source was automatically turned off as a result of paw withdrawal. A cutoff time of 20 s was applied to prevent tissue damage.
Rotarod Test. To determine whether trifluoperazine at the doses used (administered intraperitoneally or by mouth) caused locomotor impairment in animals, the locomotor ability was tested with a rotarod treadmill (model series 8; IITC Life Science, Woodland Hills, CA). Mice were first trained to stay on the rotarod revolving at 16 rpm for two consecutive 120-s trials. On the next day, locomotor activity was tested 4 h (i.e., the peak antihyperalgesic/allodynic time) after the administration of trifluoperazine (0.5 mg/kg i.p. or 1.0 mg/kg p.o.) or saline (equal volume, intraperitoneally or by mouth). The duration when a mouse stays on the rotarod was recorded. A cutoff time (i.e., maximal test time) is 300 s.
Western Blotting Analysis. The lumbar sections of the spinal cord were quickly dissected from euthanized mice and separated into the ipsilateral and contralateral halves. Tissues were quickly frozen in acetone-dry ice solution and stored Ϫ80°C or immediately processed for Western blotting analysis as described previously (Tang et al., 2006a; Luo et al., 2008) . In brief, tissues were homogenized in buffer A in the presence of phosphatase inhibitors (10 mM sodium fluoride, 10 mM sodium pyrophosphate, 1 mM sodium orthovanadate, and 1 M okadaic acid) and protease inhibitors (0.05 mg/ml bestatin, 0.05 mg/ml leupeptin, 0.05 mg/ml pepstatin, and 0.1 mg/ml phenylmethylsulfonyl fluoride). The homogenates were incubated on a rotator for 1 h and centrifuged (45,000g) for 1 h at 4°C. Protein content in the supernatant was determined by a modified Bradford method (Pierce Biotechnology, Rockford, IL). Samples were then separated by SDS-polyacrylamide gel electrophoresis and electrotransferred onto poly(vinylidene difluoride) membrane for Western blotting analyses. Antibodies including a rabbit anti-(T286/ 287)pCaMKII antibody (1:1000; Promega, Madison, WI), a rabbit anti-CaMKII antibody (1:1000; Santa Cruz Biotechnology, Inc., Santa Cruz, CA), and a mouse anti-␤-actin antibody (1:10,000; Sigma-Aldrich), and corresponding horseradish peroxidase conjugate secondary antibodies (GE Healthcare, Little Chalfont, Buckinghamshire, UK) were used. The enhanced chemiluminescence signals (Pierce Biotechnology) were captured by a ChemiDoc imaging system and analyzed with use of the Quantity One program (Bio-Rad Laboratories, Hercules, CA). Ratios of the optical densities of pCaMKII or CaMKII to those of ␤-actin were calculated for each sample.
Statistical Analysis. A two-way repeated-measures analysis of variance was used to determine differences among groups. The Student-Newman-Keuls test was used as a post hoc test. Statistical significance was established at the 95% confidence limit.
Results
Effect of Acute CaMKII Inhibition on SNL-Induced Pain Behaviors. As expected, thermal hyperalgesia and mechanical allodynia developed shortly after SNL. Within
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48 h, withdrawal latencies to radiant heat and withdrawal thresholds to probing by von Frey filaments were significantly reduced in SNL-operated mice (p Ͻ 0.001 compared with the sham group, n ϭ 8; Fig. 1 ). On day 5, when SNLinduced hyperalgesia and allodynia have fully developed, an acute administration of KN93 (30 and 45 nmol i.t.) 2 h before pain testing was able to reverse the established mechanical allodynia (Fig. 1A ) and thermal hyperalgesia (Fig. 1B) (p Ͻ 0.001 compared with the SNL group or pretreatment baseline, n ϭ 8). KN93 at the lowest dose used (15 nmol i.t.) did not show any effect on SNL-induced hyperalgesia or allodynia (p Ͼ0.05 compared with the SNL group, n ϭ 8). The same acute treatment with the kinase-inactive chemical analog KN92 (45 nmol i.t.) had no effect on SNL-induced hyperalgesia or allodynia (Fig. 1 , p Ͼ 0.05 compared with the SNL group, n ϭ 8).
To correlate the behavioral effects with the biochemical changes of CaMKII activity by KN93, not by KN92, the ipsilateral and contralateral lumbar sections of the spinal cord were dissected out on day 5 to determine the degree of CaMKII autophosphorylation (pCaMKII), which serves as a biomarker for CaMKII activity Tang et al., 2006a; Luo et al., 2008) . Compared with the sham operation, SNL significantly increased spinal pCaMKII on the ipsilateral side ( Fig. 2A , p Ͻ 0.001, n ϭ 4), but not on the contralateral side (Fig. 2C , p Ͼ 0.05, n ϭ 4). The spinal expression of total CaMKII was not significantly altered ( Fig. 2B ), suggesting that the increased CaMKII activity was largely due to enhanced autophosphorylation (i.e., activation) of existing CaMKII. In SNL-operated mice, KN93 (30 -45 nmol i.t.) significantly reversed SNL-induced activation of CaMKII (pCaMKII) ( Fig. 2A , p Ͻ0.001 compared with the SNL group, n ϭ 4). KN93 at the lowest dose used (15 nmol) did not alter pCaMKII expression, and KN92 did not affect the expression of pCaMKII ( Fig. 2A , p Ͼ 0.05 compared with the SNL group, n ϭ 4). In addition, KN93 or KN92 did not alter thermal and mechanical nociception baselines in naive mice (Luo et al., 2008) . These data suggest that acute inhibition of CaMKII by KN93 dose-dependently reversed SNL-induced thermal hyperalgesia and mechanical allodynia, consistent with the inhibitor's action on CaMKII activity.
The onset and duration of action of KN93 were investigated in another series of experiments to monitor the thermal and mechanical sensitivities for up to 24 h after administration of KN93 (intrathecal injection). The antihyperalgesic/antiallodynic effect of KN93 (30 and 45 nmol) started at 30 min and peaked at 2 h (Fig. 3) . At the highest dose, KN93 (45 nmol) completely reversed thermal hyperalgesia and tactile allodynia (p Ͼ 0.05 compared with the sham group at 2 h), and its action lasted for at least 4 h (Fig. 3) . At a lower dose, KN93 (30 nmol) completely blocked mechanical allodynia and partially suppressed thermal hyperalgesia at the peak effect time (2 h); the antiallodynic and antihyperalgesic actions lasted for 2 and 4 h, respectively (Fig. 3 ). KN93 at 15 nmol did not affect either thermal or mechanical sensitivity at any time point tested. At 8 h after administration of KN93, the antihyperalgesic/antiallodynic action of KN93 had disappeared. All SNL-operated mice, either treated or not treated with KN93, had the same thermal and mechanical sensitivities on the following day (24 h) (p Ͼ 0.05 compared with the SNL group; p Ͻ 0.001 compared with the sham group, n ϭ 8). At the peak-effect time (2 h), ED 50 values were estimated to be 26.1 Ϯ 0.3 (antiallodynia) and 29.7 Ϯ 0.1 nmol (antihyperalgesia).
Trifluoperazine Reversed SNL-Induced Hyperalgesia and Allodynia. Trifluoperazine is a clinically used antipsychotic drug that we recently discovered to inhibit CaMKII in vitro and in vivo (Tang et al., 2006b; Luo et al., 2008) . Therefore, this drug would not only provide another test of our hypothesis but also might become a potential drug therapy targeting the CaMKII signaling pathway. Five days after SNL, when thermal hyperalgesia and mechanical allodynia have fully developed, trifluoperazine (0.1-0.5 mg/kg i.p.) was administrated to determine whether the drug produced antihyperalgesic and antiallodynic actions in the SNL model of neuropathic pain. Trifluoperazine (0.5 and 0.25 mg/kg i.p.) completely reversed the established SNL-induced mechanical allodynia (Fig. 4A ) and thermal hyperalgesia (Fig. 4B ) (p Ͻ 0.001 compared with the SNL group, n ϭ 8) within 2 h, whereas at a lower dose (0.1 mg/kg i.p.), it had no effect on SNL-induced hyperalgesia or allodynia (Fig. 4) . Therefore, trifluoperazine was able to dose-dependently re- verse SNL-induced neuropathic pain behaviors. Correlating with its behavioral effect, trifluoperazine was found to suppress SNL-induced increase of spinal CaMKII activation (pCaMKII) on the ipsilateral side in a dose-dependent manner in mice (Fig. 5A ) without significantly altering the total spinal CaMKII expression (Fig. 5B) or spinal pCaMKII at the contralateral side (Fig. 5C) .
At the highest dose, trifluoperazine (0.5 mg/kg) appeared to produce analgesia in the radiant heat assay (Fig. 4B) . To better understand the nature of the drug's antihyperalgesic/ antiallodynic and possible analgesic actions, we monitored its actions for 24 h after an acute intraperitoneal administration in the SNL-or sham-operated mice (Fig. 6 ). In the mechanical sensitivity study, trifluoperazine (0.25-0.5 mg/ kg) exhibited a rapid onset of action in reversing the established SNL-induced mechanical allodynia. The antiallodynic effect started at 30 min and peaked at 4 h (Fig. 6A) . At 4 h, the ED 50 was estimated to be 0.2 Ϯ 0.0 mg/kg. The antihyperalgesic effect peaked at 2 h (EC 50 , 0.2 Ϯ 0.0 mg/kg), and lasted for at least 4 h (for a 0.25 mg/kg dose) to 8 h (for a 0.5 mg/kg dose) (Fig. 6B) . We did not find any significant action of trifluoperazine at 0.1 mg/kg on SNL-induced thermal hyperalgesia or mechanical allodynia (Figs. 4 and 6 ). On the next day (24 h after trifluoperazine), all SNL-operated 
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at ASPET Journals on July 31, 2017 jpet.aspetjournals.org groups showed thermal hyperalgesia and mechanical allodynia. These data suggest that trifluoperazine is able to acutely reverse the established SNL-induced abnormal pain behaviors with a duration of action of approximately 4 to 8 h. Only the highest dose (0.5 mg/kg) produced analgesic action in the radiant heat assay at 2 h.
Because trifluoperazine can be taken orally, we further examined whether oral trifluoperazine (via gastric gavage) was effective. Five days after the SNL operation, when thermal hyperalgesia and mechanical allodynia have fully developed, trifluoperazine dose-dependently attenuated SNLinduced mechanical allodynia (Fig. 7A ) and thermal hyperalgesia (Fig. 7B ) within 2 h after an oral administration (0.1-1 mg/kg). At the two higher doses, the drug completely (1 mg/kg) or partially (0.3 mg/kg) blocked SNL-induced pain behaviors, but it was ineffective at the lowest dose (0.1 mg/ kg). A more careful time course analysis in another series of experiments (Fig. 8) confirmed the drug's antihyperalgesic and antiallodynic actions similar to what was found after the intraperitoneal administration. Compared with intraperitoneal administration, orally administered trifluoperazine produced slightly slower onset and longer duration of action that lasted for at least 8 h, which can be accounted for by the different pharmacokinetics after the oral administration of a drug. The estimated ED 50 values at the peak time (2-4 h) were 0.3 Ϯ 0.1 mg/kg for the antiallodynic/antihyperalgesic action. Similar to the intraperitoneal injection, a weak but significant analgesic action was found in the thermal nociception test 2 h after oral administration of trifluoperazine (1 mg/kg).
One confounding factor for interpreting the antihyperal- gesic/antiallodynic actions of trifluoperazine may be that the drug causes motor deficits in animals. Next, we examined locomotor activity of the mice after the administration of trifluoperazine. Separate groups of mice were first trained on a Rotarod revolving at 16 rpm for two consecutive 120-s trials. On the next day, mice received trifluoperazine (0.5 mg/kg i.p. or 1.0 mg/kg p.o.) or equal volumes of saline (administered intraperitoneally or by mouth). Four hours later when the drug's antihyperalgesic/antiallodynic actions were at the peak, locomotor activity was examined. Trifluoperazine did not cause locomotor impairment in mice (p Ͼ 0.05 compared with the corresponding saline group, n ϭ 5; Table 1 ).
Discussion
In this study, we examined the role of CaMKII in an experimental model of neuropathic pain. Our findings supported the hypothesis that CaMKII is required for the maintenance of neuropathic pain behaviors induced by spinal nerve ligation. Such a mechanism is plausible considering that, in the primary afferent and the spinal cord, CaMKII␣ is specifically expressed in the small-to medium-diameter primary sensory neurons in the dorsal root ganglia and in the superficial laminae of the spinal cord dorsal horn. Both locations are important for the transmission and processing of nociceptive signals (Brü ggemann et al., 2000; Carlton, 2002) .
In the formalin inflammation model, the second phase of formalin-induced paw-licking behavior was significantly reduced by KN93 (Choi et al., 2006) and largely absent in CaMKII␣(T286A) mutant mice (Zeitz et al., 2004) . We found that KN93, but not its inactive analog KN92, prevented or reversed CFA-induced mechanical allodynia and thermal hyperalgesia (Luo et al., 2008) . Our data are in agreement with the findings from the persistent-inflammation model that CaMKII is critical for the presence of persistent pain. Our findings, however, are contrary to the results of a previous study where KN93 was ineffective in reversing fully developed thermal hyperalgesia and mechanical allodynia 7 days after CCI . The discrepancy may be due to the different pain models that were used. However, our previous studies have suggested that different pain states may have different degrees of CaMKII activity and, therefore, may require different doses of CaMKII inhibitors (Luo et al., 2008) . We were able to confirm the inhibition of CaMKII by KN93 or trifluoperazine at the doses that produced behavioral effects, but not at lower doses where neither significant CaMKII inhibition nor behavioral effects occurred. Another previous study had found that KN93 (120 pmol i.t.) and myristoyl-autocamtide 2-related inhibitory peptide (1 nmol i.t.) effectively reversed CCI-induced pain behaviors in mice, although experimental details were not provided (Garry et al., 2003) . Although the overall outcome of the study by Garry et al. (2003) agreed with outcome of the current study, After mechanical allodynia and thermal hyperalgesia were established 5 days after L 5 /L 6 spinal nerve ligation (SNL), mice were treated with trifluoperazine (0.1-1.0 mg/kg, gastric gavage) or saline 2 h before the thermal and mechanical sensitivity tests. Trifluoperazine dose-dependently reversed the established SNL-induced mechanical allodynia and thermal hyperalgesia. Postsurgery mechanical or thermal sensitivity was tested immediately before the treatment with trifluoperazine on day 5 after surgery (SNL or sham operation). Data are expressed in mean Ϯ S.E.M. ‫,ءءء‬ p Ͻ 0.001, compared with the sham group; † † †, p Ͻ 0.001 compared with the SNL group, n ϭ 8 for each group. the doses of KN93 used varied significantly. We found that KN93 at 15 nmol i.t. or lower was ineffective at any time point after drug administration (Fig. 3) .
Findings from our laboratory and others (Garry et al., 2003; Dai et al., 2005; Ogawa et al., 2005; Luo et al., 2008) have so far suggested a critical role of CaMKII in persistent pain. This was not supported by a study using CaMKII␣(T286A) mutant mice (Zeitz et al., 2004) . CaMKII␣(T286A) mutant mice express a form of CaMKII␣ that cannot be autophosphorylated. Therefore, CaMKII remains inactive. The second phase of formalin-induced paw-licking behavior was largely absent in CaMKII␣(T286A) mice. However, nerve injury and CFA produced similar enhancement of thermal and mechanical sensitivity in CaMKII␣ mutant and wild-type mice (Zeitz et al., 2004) . The exact cause for the discrepancy is not clear. Obviously, two different approaches were used in these studies by either chemically inhibiting CaMKII or genetically eliminating functional CaMKII. Interpreting studies using CaMKII inhibitors can be complicated by the possible loss of selectivity, especially at high doses. However, mouse transgenic/"knockout" approaches may have potential problems with compensatory changes, unmatched genetic background, or other nonspecific genomic effects.
In our studies, the effect of acute CaMKII inhibition in reversing the established persistent pain was further supported by experiments employing trifluoperazine. Trifluoperazine is a clinically used antipsychotic drug and a calmodulin inhibitor that suppresses CaMKII activity (Tang et al., 2006b; Luo et al., 2008) . Therefore, trifluoperazine not only presents a unique opportunity to test our hypothesis but also may provide a clinically useful drug for alleviating neuropathic pain by targeting the CaMKII pathway. Indeed, systemic trifluoperazine (intraperitoneally or by mouth) dosedependently reversed mechanical allodynia and thermal hyperalgesia in SNL-operated mice. Therefore, we have used two very different drugs that converge on the same CaMKII mechanism that was confirmed by biochemical analysis. These data strongly indicate that KN93 and trifluoperazine exhibited their antihyperalgesic/antiallodynic actions through CaMKII. It is unlikely that another mechanism could have accounted for the action of trifluoperazine and KN93 (controlled by KN92). On the other hand, we can not exclude such a possibility.
Our data suggest that trifluoperazine may become useful for the treatment of neuropathic pain, although it has yet to be demonstrated in clinical settings. The side effects associated with the drug, including dystonia, hyperprolactinemia, akathisia, sedation, hypotension, confusion, dry mouth, blurred vision, and urinary retention, may become a problem (Marques et al., 2004) . These side effects are probably caused by the drug's pharmacologic actions of blocking the dopamine receptors and, to a lesser degree, antagonizing the cholinergic, histaminic, and ␣-adrenergic receptors (Marques et al., 2004) . However, the antiallodynic/antihyperalgesic doses of trifluoperazine, with ED 50 of 0.2 mg/kg i.p. to 0.3 mg/kg p.o., are only one tenth of the antipsychotic doses. Trifluoperazine exhibited similar potency in preventing or reversing CFAinduced persistent pain behaviors (Luo et al., 2008) . The antipsychotic effect ED 50 of the drug has been reported to be approximately 3 to 5 mg/kg (Reiss et al., 1994) . Moreover, at the antihyperalgesic/antiallodynic doses (0.5 mg/kg i.p. or 1 mg/kg p.o.), trifluoperazine did not cause locomotor impairment, which was in agreement with previous findings in the open field test (DeLong et al., 1985) . One previous study reported that trifluoperazine (intrathecal injection.) produced either analgesia (at low doses) or hyperalgesia (at a high dose) in a formalin-induced inflammatory pain model (Golbidi et al., 2002) . In naive mice, trifluoperazine (0.5 mg/kg i.p.) produced a weak but significant thermal hyperalgesic action 8 h after the drug administration; no mechanical hyperalgesia was observed (Luo et al., 2008) . We did not observe hyperalgesia activity in the SNL-treated mice. Instead, trifluoperazine at the highest dose given (0.5 mg/kg i.p. or 1 mg/kg p.o.) produced an analgesic action in the thermal (but not mechanical) nociception test, 2 h after administration, on top of its antihyperalgesic and antiallodynic effects. The SNL-induced CaMKII activation occurred only in the ipsilateral but not the contralateral spinal cord. Similar unilateral activation of CaMKII was found after CCI operation in rats .
Although the downstream effect of CaMKII in leading to persistent pain is not entirely clear, its interaction with the NMDA receptors may provide a plausible mechanism. There seemed to be a feed-forward interaction between the NMDA receptors and CaMKII in the persistent pain state (Luo et al., 2008) . Phosphorylation of NMDA receptors by CaMKII has been shown to enhance the NMDA receptor function, leading to the influx of Ca 2ϩ through the channels (Kitamura et al., 1993) . Therefore, activation of CaMKII as a result of nerve injury can potentially increase the activity of the NMDA receptors leading to Ca 2ϩ influx. Increased cytosolic Ca 2ϩ ions bind and change the conformation of CaM, which in turn leads to the activation of more CaMKII (Strack et al., 1997) . It has been demonstrated that NMDA receptor antagonists, administered before peripheral nerve injuries, suppress the onset of hyperalgesia. They also attenuated fully developed hyperalgesia when administered after the injury (e.g., Dickenson et al., 1997; Zhang et al., 1998; Dai et al., 2005) . Therefore, CaMKII may work in concert with NMDA receptors leading to the manifestation of neuropathic pain. There may also be a functional interaction between CaMKII␣ and transient receptor potential vanilloid type 1 receptor. In rat trigeminal ganglion neurons, it was found that capsaicin increased CaMKII␣ activity in the capsaicin receptor transient receptor potential vanilloid type 1 receptor-positive neurons (Price et al., 2005) . In these trigeminal ganglion neurons, capsaicin-or n-arachidonoyl-dopamine-evoked calcitonin gene-related peptide release was inhibited by KN93 (Price et al., 2005) . In summary, our findings suggest the critical involvement of CaMKII in maintaining experimental neuropathic pain. Such data are critical for designing new pain therapies, because most patients with persistent abnormal pain seek medical treatment after nerve or tissue injuries. To begin to translate these findings to clinically useful drugs, we further found that trifluoperazine at relatively low doses (approximately one-tenth of its antipsychotic doses) could effectively block SNL-induced abnormal pain behaviors. Although the drug is not expected to be selective for CaMKII and has side effects, it is orally available and has been used in humans for more than 30 years. Therefore, trifluoperazine may provide a new drug candidate for the treatment of neuropathic pain by targeting the CaMKII pathways. 
